Open AccessResponse assessment in metronomic chemotherapy: RECIST or PERCIST?
Author(s) -
Archi Agrawal,
Nilendu Purandare,
Sneha Shah,
Ameya Puranik,
Shripad Banavali,
Venkatesh Rangarajan
Publication year - 2014
Publication title -
indian journal of nuclear medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.261
H-Index - 13
eISSN - 0972-3919
pISSN - 0974-0244
DOI - 10.4103/0972-3919.130285
Subject(s) - medicine , response evaluation criteria in solid tumors , concordance , positron emission tomography , nuclear medicine , progressive disease , magnetic resonance imaging , chemotherapy , radiology
Metronomic chemotherapy (MC) is a novel therapeutic variation for resistant cancers, wherein chemotherapeutic drugs are administrated in low doses with no prolonged drug-free break. It lessens the level of toxicity, is better tolerated and enhances the quality of life. This retrospective analysis was undertaken to evaluate whether anatomical (computed tomography [CT]) or functional (positron emission tomography [PET]) imaging be used for response assessment in patients on MC.